No Increase Seen in HPV Vaccination Coverage From 2019 to 2022
By Elana Gotkine HealthDay Reporter
THURSDAY, Feb. 22, 2024 -- Human papillomavirus (HPV) vaccination rates did not increase from 2019 to 2022, according to a study published online Feb. 20 in JAMA Network Open.
Kalyani Sonawane, Ph.D., from the Medical University of South Carolina in Charleston, and colleagues analyzed data for U.S. participants aged 18 to 26 years from the 2018, 2019, and 2022 National Health Interview Survey to examine HPV vaccination coverage during the pandemic.
In 2022, 2,159 adults aged 18 to 26 years with HPV vaccination information were identified. The researchers found that 47.4 percent of these adults reported receiving one or more vaccine doses. The HPV vaccination rate increased from 2018 to 2019 (39.9 to 47.0 percent), but no significant change was seen for 2019 to 2022. More women than men were vaccinated in 2022 (57.2 versus 37.3 percent). In 2022, coverage was similar for Hispanics, non-Hispanic Blacks, and participants of other races and ethnicities compared with non-Hispanic Whites. Higher coverage was seen for lesbian, gay, bisexual, and other sexual orientation groups versus heterosexual women (70.6 versus 53.6 percent) and for gay, bisexual, and other sexual orientation versus heterosexual men (52.7 versus 36.2 percent). Uninsured men and women had lower coverage than their insured counterparts.
"Human papillomavirus vaccination coverage among young adults did not increase during the COVID-19 pandemic compared with prior years," the authors write. "This finding likely reflects pandemic-related disruptions in initiating the HPV vaccine among young adults."
Two authors disclosed ties to Value Analytics Labs; one disclosed ties to Merck.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Primary HPV Screening Intervals Could Be Extended
FRIDAY, May 24, 2024 -- Primary human papillomavirus (HPV) screening intervals could be extended, with the risk for cervical precancer or worse (CIN2+) eight years after negative...
ASCO: HPV Vaccination Positively Affecting More Than Just Cervical Cancer Risk
THURSDAY, May 23, 2024 -- Human papillomavirus (HPV) vaccination is associated with reduced odds of several types of HPV-related cancers, not just cervical cancer, according to a...
Preparedness for HPAI A(H5N1) Virus Varies Across Jurisdictions
TUESDAY, May 21, 2024 -- Variation is seen in preparedness and response to highly pathogenic avian influenza (HPAI) A(H5N1) viruses, according to a research letter published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.